SEC Form 10-Q filed by LeonaBio Inc.
$LONA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2026 | $20.00 | Overweight | Piper Sandler |
| 2/26/2026 | Overweight | Cantor Fitzgerald | |
| 2/19/2026 | $10.00 | Neutral → Outperform | Mizuho |
BOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Javier San Martin, MD, Chief Medical Officer of LeonaBio, delivered a presentation at the 5th Annual ALS Drug Development Summit taking place June 2-4, 2026 in Boston, Massachusetts. The presentation, titled "Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies," provided an overview of the company's brelgometon (ATH-1105) clinical development program in amyotrophic lateral sclerosis (ALS). Brelgometon is an or
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA. Details are as follows: 5th Annual ALS Drug Development Summit Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive MethodologiesSession Title: Redefining Biomarkers and Trial Design to Accelerate Neurodeg
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- Leon
Piper Sandler initiated coverage of LeonaBio with a rating of Overweight and set a new price target of $20.00
Cantor Fitzgerald initiated coverage of LeonaBio with a rating of Overweight
Mizuho upgraded LeonaBio from Neutral to Outperform and set a new price target of $10.00
DEFA14A - LeonaBio, Inc. (0001620463) (Filer)
DEF 14A - LeonaBio, Inc. (0001620463) (Filer)
SCHEDULE 13D/A - LeonaBio, Inc. (0001620463) (Subject)
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- Leon
BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board of Directors, effective as of May 5, 2026. The company also announced that John Fluke, Jr., who has served on the Board of Directors since 2014, retired effective May 4, 2026. "We are delighted to welcome Fred, Natalie, and Peter to LeonaBio's Board of Directors," said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. "Collectively, they bring
BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio's business development strategy and execution, with responsibility for licensing, partnership strategy, and corporate development initiatives. Mr. Kubik previously served as a strategic consultant to LeonaBio, where he played an instrumental role in the transformational transaction announced in December 2025, in which LeonaBio acquired rights to the Phase 3
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)